BioPoint Inc

03/18/2026

The FDA approved J&J’s first targeted oral IL-23 therapy for plaque psoriasis, offering a new pill alternative to injectable treatments. The drug marks a first-in-class approach targeting a key inflammation pathway. https://www.biospace.com/fda/j-j-wins-fda-nod-for-first-targeted-oral-anti-il-23-therapy-for-plaque-psoriasis

Icotyde, co-developed by Johnson & Johnson and Protagonist Therapeutics, is backed by data from the Phase 3 ICONIC program, which, among other advantages, showed significant superiority over Bristol Myers Squibb’s Sotyktu.

03/17/2026

The article highlights the top 10 blockbuster drugs losing U.S. exclusivity in 2026, opening the door to generics and biosimilars across multiple therapeutic areas. These patent expirations are expected to drive significant revenue loss and reshape the competitive landscape for major pharma companies. https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2026

In an era of pharma megablockbusters, industry watchers’ attention naturally drifts toward the biggest drugs in the business. Lately, those ranks have been filled by the ubiquitous diabetes and obesity drugs from Eli Lilly and Novo Nordisk, plus Merck’s cancer superstar Keytruda and other major ...

03/16/2026

Join us for our session on Monday, April 13th from 4:30pm - 5:00pm on the stage with BioPoint Speaker Jay Destino discussing How Outsourcing Partners Can Support Biotech Companies in a Financially Constrained Environment. You don't want to miss it!

03/13/2026

The FDA expanded approval of GSK’s RSV vaccine Arexvy to adults ages 18–49 who are at higher risk of severe disease. The move helps GSK keep pace with RSV vaccine rivals Pfizer and Moderna in the growing market. https://www.fiercepharma.com/pharma/gsk-catches-pfizer-moderna-gaining-fda-expansion-arexvy

GSK has secured an FDA exp | GSK has secured an FDA expansion for its respiratory syncytial virus vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus. The green light puts GSK on a level playing field with Pfizer and Moderna, whi...

03/12/2026

We hope to see you there!

03/12/2026

The FDA launched a new unified adverse-event monitoring platform (AEMS) to replace multiple outdated reporting systems. The streamlined system will provide real-time safety data across FDA-regulated products and is expected to save about $120 million over five years. https://www.fiercepharma.com/pharma/fda-rolls-out-new-streamlined-adverse-event-monitoring-system

It’s out with the old, in with the new at the FDA as the agency is unveiling a new adverse events monitoring system that joins several reporting systems into one unified platform, an effort that’s | The new platform combines seven different adverse event dashboards into one, an effort that could...

03/11/2026

BioNTech founders Ugur Sahin and Özlem Türeci plan to leave the company to launch a new biotech focused on next-generation mRNA therapies. Their departure comes as BioNTech shifts toward becoming a multi-product commercial biotech. https://www.biospace.com/business/biontech-founders-to-leave-famed-mrna-biotech-for-new-venture

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

03/10/2026

The FDA approved leucovorin to treat an ultrarare form of cerebral folate deficiency linked to autism-like symptoms. The decision was based on case reports and literature rather than a clinical trial due to the condition’s rarity. https://www.fiercepharma.com/pharma/fda-approves-leucovorin-ultra-rare-cerebral-folate-deficiency-subset-without-clinical-trial

About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an exciting therapy that may benefit large numbers of children who suffer from autism” during a White H...

03/09/2026

Be sure to stop by and say hello at Booth #30! Will we see you there?

03/09/2026

Ipsen is withdrawing its cancer drug Tazverik after a study linked the treatment to an increased risk of secondary blood cancers. The company is also halting related clinical trials due to the safety concerns. https://www.biospace.com/business/ipsen-pulls-cancer-drug-amid-risk-of-secondary-malignancies

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.

03/06/2026

Merck KGaA expects no U.S. sales of its multiple sclerosis drug Mavenclad after March 2026 as generic competition enters the market. The outlook follows failed patent defenses that opened the door for generic versions. https://www.fiercepharma.com/pharma/after-generic-defense-fails-merck-kgaa-expects-no-us-mavenclad-sales-after-march

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S. | After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go o...

03/05/2026

Alnylam and Tenaya Therapeutics signed a collaboration worth up to $1B+ to discover new genetic targets for heart disease using RNAi technology. The partnership combines Tenaya’s target discovery platform with Alnylam’s RNA interference expertise. https://www.biospace.com/deals/alnylam-unites-with-tenaya-in-potential-1b-pact-to-find-new-genetic-heart-disease-targets

The alliance, which pairs Tenaya’s modality agnostic target identification and validation capabilities with Alnylam’s deep experience in RNA interference therapeutics, comes during a period of resurgence for the cardiovascular space.